

=> file caplus medline biosis embase  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
36.94	37.15

FILE 'CPLUS' ENTERED AT 17:31:23 ON 19 SEP 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 17:31:23 ON 19 SEP 2006

FILE 'BIOSIS' ENTERED AT 17:31:23 ON 19 SEP 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 17:31:23 ON 19 SEP 2006  
Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s phytanic acid or phytenic acid or phytol or 14721-66-5/rn or 3653-46-1/rn or  
150-86-7/rn  
'RN' IS NOT A VALID FIELD CODE  
'RN' IS NOT A VALID FIELD CODE  
'RN' IS NOT A VALID FIELD CODE  
L3 5975 PHYTANIC ACID OR PHYTENIC ACID OR PHYTOL OR 14721-66-5/RN OR  
3653-46-1/RN OR 150-86-7/RN

=> s l3 and (phytanic or phytenic)  
L4 2097 L3 AND (PHYTANIC OR PHYTENIC)

=> s l3 or (phytanic or phytenic)  
L5 6013 L3 OR (PHYTANIC OR PHYTENIC)

=> s l5 and (diabetes or niddm or hyperinsulinemia or (insulin adj resistance))  
L6 52 L5 AND (DIABETES OR NIDDM OR HYPERINSULINEMIA OR (INSULIN ADJ  
RESISTANCE))

=> dup rem 16  
PROCESSING COMPLETED FOR L6  
L7 36 DUP REM L6 (16 DUPLICATES REMOVED)

=> focus  
PROCESSING COMPLETED FOR L7  
L8 36 FOCUS L7 1-

=> d ibib abs hitstr 1-36

L8 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2002:104617 CAPLUS  
DOCUMENT NUMBER: 136:145248  
TITLE: Use of phytanic acid for the  
treatment of diabetes and other conditions  
associated with impaired glucose tolerance  
INVENTOR(S): Fluehmann, Beat; Heim, Manuel; Hunziker, Willi; Weber,  
Peter  
PATENT ASSIGNEE(S): Roche Vitamins A.-G., Switz.  
SOURCE: Eur. Pat. Appl., 29 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1177789	A2	20020206	EP 2001-118230	20010730
EP 1177789	A3	20030129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002082298	A1	20020627	US 2001-915152	20010725
US 6784207	B2	20040831		
JP 2002104964	A2	20020410	JP 2001-233070	20010801
CA 2353805	AA	20020204	CA 2001-2353805	20010803
BR 2001003209	A	20020326	BR 2001-3209	20010803
CN 1365667	A	20020828	CN 2001-124878	20010803
US 2004138181	A1	20040715	US 2004-766118	20040127
PRIORITY APPLN. INFO.:			EP 2000-116848	A 20000804
			US 2001-915152	A3 20010725

AB A method is provided for the treatment or prevention of preferably non-insulin dependent (NIDDM or so-called Type II) **diabetes mellitus**, or other conditions associated with impaired glucose tolerance, e.g. obesity, and in particular to the use of **phytanic acid** derivs. for the treatment or prevention.

IT 150-86-7, **Phytol**


RL: BSU (Biological study, unclassified); BIOL (Biological study) (**phytanic acid** for the treatment of **diabetes** and other conditions associated with impaired glucose tolerance)

RN 150-86-7 CAPLUS

CN 2-Hexadecen-1-ol, 3,7,11,15-tetramethyl-, (2E,7R,11R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 14721-66-5, **Phytanic acid**


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(**phytanic acid** for the treatment of **diabetes** and other conditions associated with impaired glucose tolerance)

RN 14721-66-5 CAPLUS

CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:441439 CAPLUS

DOCUMENT NUMBER: 142:487490

TITLE: Use of **phytanic acid** for treating **diabetes**

INVENTOR(S): Zhou, Dingcheng

PATENT ASSIGNEE(S): Beiyi Medicine Sci. & Tech. Co., Ltd., Shanghai, Peop. Rep. China

SOURCE: Faming Zhanli Shenqing Gongkai Shuomingshu, No pp.

given  
 CODEN: CNXXEV  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Chinese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1507871	A	20040630	CN 2002-154971	20021216
			CN 2002-154971	20021216

PRIORITY APPLN. INFO.:


AB The present invention relates to an application of **phytanic acid** for curing **diabetes**. Said invented medicine is prepared by adopting **phytanic acid** or its derivative and pharmaceutically-acceptable additive and/or adjuvant. The described derivative includes salts with alkali metal and alkali earth metal or their pharmaceutically-acceptable solvent compound. The tests show that said invented medicine has good therapeutic effect for diabetic, specially, for patient with hyperglycemia, hyperlipemia and hypertension.

IT 14721-66-5, **Phytanic acid**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(use of **phytanic acid** and its salts for treating **diabetes**)

RN 14721-66-5 CAPLUS

CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:343937 CAPLUS

DOCUMENT NUMBER: 137:304593

TITLE: **Phytanic acid**, a natural peroxisome proliferator-activated receptor agonist, regulates glucose metabolism in rat primary hepatocytes

AUTHOR(S): Heim, Manuel; Johnson, James; Boess, Franziska; Bendik, Igor; Weber, Peter; Hunziker, Willi; Fluehmann, Beat

CORPORATE SOURCE: Research and Development, Department of Human Nutrition and Health, Roche Vitamins, Basel, 4070, Switz.

SOURCE: FASEB Journal (2002), 16(7), 718-720, 10.1096/fj.01-0816fje

CODEN: FAJOEC; ISSN: 0892-6638

PUBLISHER: Federation of American Societies for Experimental Biology


DOCUMENT TYPE: Journal

LANGUAGE: English

AB **Phytanic acid**, a metabolite of chlorophyll, is part of the human diet and is present in normal human serum at low micromolar concns. It was previously shown to be a ligand of the 9-cis-retinoic acid receptor and peroxisome proliferator-activated receptor (PPAR)  $\alpha$ . PPAR agonists are widely used in the treatment of type 2 **diabetes**. This work reports that **phytanic acid** is not only a transactivator of PPAR $\alpha$ , but it also acts via PPAR $\beta$  and PPAR $\gamma$  in CV-1 cells cotransfected with the resp. full-length receptor and an acyl-CoA oxidase-PPAR-responsive element-luciferase construct. In contrast to other fatty acids, **phytanic**

acid at physiol. concns. enhanced the uptake of 2-deoxy-D-glucose in rat primary hepatocytes. This result could be explained by the increase in the expression of mRNAs for glucose transporters-1 and -2 and glucokinase, as determined by quant. real-time reverse transcriptase-polymerase chain reaction. Compared with the PPAR $\gamma$ -specific agonist ciglitazone, **phytanic acid** exerted only minor effects on the differentiation of C3H10T1/2 cells into mature adipocytes. These results demonstrate that **phytanic acid** acts via different PPAR isoforms to modulate expression of genes involved in glucose metabolism, thus suggesting a potential role of **phytanic acid** in the management of insulin resistance.


IT 14721-66-5, **Phytanic acid**  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (phytanic acid, a peroxisome proliferator-activated receptor agonist, regulation of glucose metabolism in hepatocytes)  
 RN 14721-66-5 CAPLUS  
 CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2001:219080 CAPLUS  
 DOCUMENT NUMBER: 135:175058  
 TITLE: The chlorophyll metabolite **phytanic acid** is a natural retinoid - potential for treatment and prevention of **diabetes**  
 McCarty, M. F.  
 AUTHOR(S):  
 CORPORATE SOURCE: Pantothen Laboratories, San Diego, CA, 92109, USA  
 SOURCE: Medical Hypotheses (2001), 56(2), 217-219  
 CODEN: MEHYDY; ISSN: 0306-9877  
 PUBLISHER: Churchill Livingstone  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Synthetic ligands of the retinoid X receptor (RXR) have shown antidiabetic activity in mice, apparently owing to the fact that they stimulate the transcriptional activity of PPAR- $\gamma$ /RXR heterodimers, much like thiazolidinedione drugs. The chlorophyll metabolite **phytanic acid** was shown to be a natural ligand for RXR, active in concns. near its physiol. levels. It is thus reasonable to suspect that **phytanic acid** may have utility for treatment and prevention of human type 2 **diabetes**. **Phytanic acid** may mimic or complement various effects of conjugated linoleic acids, which were shown to activate PPAR- $\gamma$ /RXR and prevent rodent **diabetes**. Administration of hydrolyzed chlorophyll may represent the most cost-effective strategy for raising human tissue levels of **phytanic acid**.


IT 14721-66-5, **Phytanic acid**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (phytanic acid for treatment and prevention of **diabetes**)  
 RN 14721-66-5 CAPLUS  
 CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:441299 CAPLUS  
 DOCUMENT NUMBER: 143:1297  
 TITLE: Medicine for treating **diabetes** and its complication  
 INVENTOR(S): Zhou, Dingcheng  
 PATENT ASSIGNEE(S): Shanghai Beiyi Medicine Sci-Tech Co., Ltd., Peop. Rep. China  
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, No pp. given  
 CODEN: CNXXEV  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Chinese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1506049	A	20040623	CN 2002-150936	20021205
PRIORITY APPLN. INFO.:			CN 2002-150936	20021205
AB	The medicine for treating <b>diabetes</b> and its complication is compounded with <b>phytanic acid</b> or its derivative, pharmaceutically acceptable additive and/or assistant. The derivative may be alkali metal salt or alkali earth metal salts of <b>phytanic acid</b> or their pharmaceutically acceptable solution. Experiment shows that <b>phytanic acid</b> and its derivative have the activity of raising the taking of liver glucose and eliminating serum glucose and the activity is expressed by gene in enzyme inducing or stimulating insulin secretion. The present invention has excellent curative effect on <b>diabetes</b> , especially <b>diabetes</b> companied with hyperlipidemia, hypercholesterolemia, hypertension, obesity and <b>hyperinsulinemia</b> .			
IT	14721-66-5, <b>Phytanic acid</b> RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (medicine for treating <b>diabetes</b> and its complication)			
RN	14721-66-5 CAPLUS			
CN	Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)			




L8 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:624408 CAPLUS  
 DOCUMENT NUMBER: 138:348534  
 TITLE: The chlorophyll-derived metabolite **phytanic acid** induces white adipocyte differentiation  
 AUTHOR(S): Schlueter, A.; Yubero, P.; Iglesias, R.; Giralt, M.; Villarroya, F.  
 CORPORATE SOURCE: Department de Bioquimica i Biologia Molecular,

SOURCE: Universitat de Barcelona, Barcelona, Spain  
International Journal of Obesity (2002), 26(9),  
1277-1280  
CODEN: IJOBDP; ISSN: 0307-0565  
PUBLISHER: Nature Publishing Group  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB **Phytanic acid** is a derivative of the **phytol** side-chain of chlorophyll. It appears in humans following the ingestion of fat-containing foods and is present in human blood at a low micromolar concentration. It may activate retinoid X receptors (RXR) or peroxisome proliferator-activated receptor (PPAR)  $\alpha$  in vitro. **Phytanic acid** induced the adipocyte differentiation of 3T3-L1 cells in culture as assessed by accumulation of lipid droplets and induction of the aP2 mRNA marker. This effect was mimicked by a synthetic activator of RXR but not by a PPAR $\alpha$  agonist or by palmitic acid. In human pre-adipocytes in primary culture, **phytanic acid** also induced adipocyte differentiation. These findings indicate that **phytanic acid** may act as a natural rexinoid in adipose cells and suggest a potential use in the treatment of human type 2 diabetes and obesity.

IT 14721-66-5, **Phytanic acid**  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chlorophyll-derived metabolite **phytanic acid**  
induces white adipocyte differentiation)  
RN 14721-66-5 CAPLUS  
CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:949902 CAPLUS  
DOCUMENT NUMBER: 142:328541  
TITLE: Nutraceutical resources for **diabetes** prevention - an update  
AUTHOR(S): McCarty, Mark F.  
CORPORATE SOURCE: NutriGuard Research, Encinitas, CA, 92024, USA  
SOURCE: Medical Hypotheses (2004), Volume Date 2005, 64(1),  
151-158  
CODEN: MEHYDY; ISSN: 0306-9877  
PUBLISHER: Elsevier Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
AB A review. There is considerable need for safe agents that can reduce risk for **diabetes** in at-risk subjects. Although certain drugs - including metformin, acarbose, and orlistat - have shown **diabetes** -preventive activity in large randomized studies, nutraceuticals have potential in this regard as well. Natural agents which slow carbohydrate absorption may mimic the protective effect of acarbose; these include: soluble fiber - most notably glucomannan; chlorogenic acid - likely responsible for reduction in **diabetes** risk associated with heavy coffee intake; and legume-derived  $\alpha$ -amylase inhibitors. There does not appear to be a natural lipase inhibitor functionally equivalent to orlistat, although there are poorly documented claims for Cassia nomame exts. Metformin's efficacy reflects activation of AMP-activated kinase; there is

preliminary evidence that certain compds. in barley malt have similar activity, without the side effects associated with metformin. In supraphysiol. concns., biotin directly activates soluble guanylate cyclase; this implies that, at some sufficient intake, biotin should exert effects on  $\beta$  cells, the liver, and skeletal muscle that favor good glucose tolerance and maintenance of effective  $\beta$  cell function. Good magnesium status is associated with reduced **diabetes** risk and superior insulin sensitivity in recent epidemiol.; ample intakes of chromium picolinate appear to promote insulin sensitivity in many individuals and improve glycemic control in some diabetics; calcium/vitamin D may help preserve insulin sensitivity by preventing secondary hyperparathyroidism. Although conjugated linoleic acid - like thiazolidinediones, a PPAR- $\gamma$  agonist - has not aided insulin sensitivity in clin. trials, the natural rexinoid **phytanic acid** exerts thiazolidinedione-like effect in animals and cell cultures, and merits clin. examination. Other natural agents with the potential to treat and possibly prevent **diabetes** include exts. of bitter melon and of cinnamon. Nutraceuticals featuring meaningful doses of combinations of these agents would likely have substantial **diabetes**-preventive efficacy, and presumably could be marketed legally as aids to good glucose tolerance and insulin sensitivity.

REFERENCE COUNT: 123 THERE ARE 123 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:182642 CAPLUS

DOCUMENT NUMBER: 140:216524

TITLE: Novel nutraceutical compositions comprising biotin

INVENTOR(S): Eggersdorfer, Manfred Ludwig; Raederstorff, Daniel; Teixeira, Sandra Renata; Weber, Peter

PATENT ASSIGNEE(S): DSM IP Assets B.V., Neth.

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004017766	A1	20040304	WO 2003-EP9112	20030818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003266287	A1	20040311	AU 2003-266287	20030818
EP 1536698	A1	20050608	EP 2003-792352	20030818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1678203	A	20051005	CN 2003-819982	20030818
JP 2005536543	T2	20051202	JP 2004-530180	20030818
US 2005256178	A1	20051117	US 2005-525348	20050222
PRIORITY APPLN. INFO.:			EP 2002-18847	A 20020823
			EP 2003-14625	A 20030626
			WO 2003-EP9112	W 20030818

AB Nutraceutical compns. comprise biotin in an amount sufficient to administer


to a subject a daily dosage of 0.01 mg per kg body weight to about 3 mg per kg body weight and at least one addnl. component selected from pantethine or a metabolite thereof, EGCG, **phytanic acid**, lipoic acid and policosanol. The compns. are useful for the treatment of both type 1 and 2 **diabetes**, and for the prevention of type 2 **diabetes** in those individuals with **pre-diabetes**, or impaired glucose tolerance (IGT) or obesity.

IT 14721-66-5, **Phytanic acid**

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(nutraceutical compns. comprising biotin for treatment of **diabetes**, glucose tolerance and obesity)

RN 14721-66-5 CAPLUS

CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:283266 CAPLUS

DOCUMENT NUMBER: 142:309913

TITLE: Compositions for the treatment and prevention of **diabetes mellitus**

INVENTOR(S): Raederstorff, Daniel; Teixeira, Sandra Renata; Wang, Ying; Weber, Peter; Wolfram, Swen

PATENT ASSIGNEE(S): DSM IP Assets B.V., Neth.

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027661	A1	20050331	WO 2004-EP10283	20040915
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1662906	A1	20060607	EP 2004-765197	20040915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.:		EP 2003-21447	A 20030923	
		WO 2004-EP10283	W 20040915	
AB	Compns. comprising a catechin as found in green tea, e.g., epigallocatechin gallate, and ligand which activates the peroxisome proliferator-activated receptor gamma (PPAR-gamma) are useful for the treatment and prevention of <b>diabetes mellitus</b> .			
IT	14721-66-5, <b>Phytanic acid</b>			

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(comps. for treatment and prevention of **diabetes mellitus**)  
RN 14721-66-5 CAPLUS  
CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 36 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
ACCESSION NUMBER: 2004:396833 BIOSIS  
DOCUMENT NUMBER: PREV200400402240  
TITLE: **Phytanic acid derivative compositions.**  
AUTHOR(S): Fluehmann, Beat [Inventor, Reprint Author]; Hunziker, Willi [Inventor]  
CORPORATE SOURCE: Zurich, Switzerland  
ASSIGNEE: Roche Vitamins Inc.  
PATENT INFORMATION: US 6784207 20040831  
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Aug 31 2004) Vol. 1285, No. 5.  
<http://www.uspto.gov/web/menu/patdata.html>. e-file.  
ISSN: 0098-1133 (ISSN print).  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
ENTRY DATE: Entered STN: 13 Oct 2004  
Last Updated on STN: 13 Oct 2004

AB The present invention is a method for the treatment or prevention of preferably non-insulin dependent (NIDDM or so-called Type II) **diabetes mellitus**, or other conditions associated with impaired glucose tolerance such as obesity, and in particular to the use of **phytanic acid** derivatives for the said treatment and/or prevention. A method of making a composition for the treatment or prevention of non-insulin dependent **diabetes mellitus** and related diseases comprising combining **phytanic acid** or derivatives thereof with a pharmaceutically acceptable additive or adjuvant, and a composition for the treatment or prevention of non-insulin dependent **diabetes mellitus** comprising **phytanic acid** or derivatives thereof are also provided.

L8 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1220665 CAPLUS  
DOCUMENT NUMBER: 143:466228  
TITLE: Use of targeted oxidative therapeutic formulation in treatment of **diabetes** and obesity  
INVENTOR(S): Hofmann, Robert F.  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 34 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2005107728	A2	20051117	WO 2005-US15846	20050505

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005272714 A1 20051208 US 2005-122907 20050505

PRIORITY APPLN. INFO.: US 2004-568542P P 20040506

AB A pharmaceutical formulation contains peroxide species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxidizing agent, such as ozone; a penetrating solvent, such as DMSO; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The formulation is used to effectively treat patients affected with **diabetes** and obesity. Thus, geraniol was subjected to ozonolysis, and the ozonized product 0.54, DMSO 98.00, hematoporphyrin 0.83, methylnaphthoquinone 0.24, and Rose bengal 0.39%.

L8 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:251322 CAPLUS

DOCUMENT NUMBER: 140:385310

TITLE: Retinoids and retinoid receptors in the control of energy balance: novel pharmacological strategies in obesity and **diabetes**

AUTHOR(S): Villarroya, F.; Iglesias, R.; Giralt, M.

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, E-08028, Spain

SOURCE: Current Medicinal Chemistry (2004), 11(6), 795-805

CODEN: CMCHE7; ISSN: 0929-8673

PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English


AB A review. Obesity and type II **diabetes** are closely related metabolic diseases with an increasing incidence worldwide. No clear-cut pharmacol. treatment for these complex metabolic disturbances is available despite current efforts. New directions and perspectives for the pharmacol. or nutritional treatment of these diseases should be defined. In recent years, a growing body of evidence shows that retinoids and retinoic acid receptors are involved in the control of biol. aspects (e.g. adiposity and energy expenditure mechanisms), which offers great potential for research on the treatment of obesity and type II **diabetes**.

All-trans retinoic acid is known to inhibit adipocyte differentiation, whereas, mols. activating the retinoid X-receptor (rexinoids) promote the differentiation of adipocytes. Treatment with rexinoids ameliorates glycemic control in rodent models of type II **diabetes** and obesity, although other findings indicate similar pos. effects by inhibiting the receptor. Moreover, natural products of dietary origin, such as **phytanic acid** can activate RXR and thus, trigger adipose cell differentiation. Finally, the activation of retinoic acid receptors or retinoid X receptors has been reported to induce the gene expression of uncoupling proteins, which are mitochondrial proteins involved in the regulation of energy expenditure and fatty acid metabolism. Further research is required to exploit the capacities of the retinoid-dependent pathways of regulation of adiposity, insulin sensitivity and energy expenditure for drug development in metabolic disturbances.

REFERENCE COUNT: 131 THERE ARE 131 CITED REFERENCES AVAILABLE FOR

THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT


L8 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:1088101 CAPLUS  
DOCUMENT NUMBER: 143:4824  
TITLE: Up-regulation of PPAR $\gamma$  coactivator-1 $\alpha$  as a strategy for preventing and reversing insulin resistance and obesity  
AUTHOR(S): McCarty, Mark F.  
CORPORATE SOURCE: NutriGuard Research, Encinitas, CA, 92024, USA  
SOURCE: Medical Hypotheses (2005), 64(2), 399-407  
CODEN: MEHYDY; ISSN: 0306-9877  
PUBLISHER: Elsevier Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
AB A review. Excessive accumulation of triglycerides and certain fatty acid derivs. in skeletal muscle and other tissues appears to mediate many of the adverse effects of insulin resistance syndrome. Although fatty diets and obesity can promote such accumulation, deficient capacity for fatty acid oxidation can also contribute in this regard. Indeed, in subjects who are insulin resistant, diabetic, and/or obese, fatty acid oxidation by skeletal muscle tends to be inefficient, reflecting decreased expression of mitochondria and mitochondrial enzymes in muscle. This phenomenon is not corrected by weight loss, is not simply reflective of subnormal phys. activity, and is also seen in lean first-degree relatives of diabetics; thus, it appears to be primarily attributable to genetic factors. Recent studies indicate that decreased expression of PPAR $\gamma$  coactivator-1 $\alpha$  (PGC-1 $\alpha$ ), a "master switch" which induces mitochondrial biogenesis by supporting the transcriptional activity of the nuclear respiratory factors, may largely account for the diminished oxidative capacity of subjects prone to insulin resistance. Thus, feasible measures which up-regulate PGC-1 $\alpha$  may be useful for preventing and treating insulin resistance and obesity. These may include exercise training, metformin and other agents which stimulate AMP-activated kinase, high-dose biotin, and PPAR $\delta$  agonists. Drugs which are specific agonists for PPAR $\delta$  show remarkable efficacy in rodent models of insulin resistance, diabetes, and obesity, and are currently being evaluated clin. **Phytanic acid**, a branched-chain fatty acid found in omnivore diets, can also activate PPAR $\delta$ , and thus should be examined with respect to its impact on mitochondrial biogenesis and insulin sensitivity.  
IT 14721-66-5, **Phytanic acid**  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(phytaic acid branch chain fatty acid found in omnivore diets can also activate PPAR $\alpha$ )  
RN 14721-66-5 CAPLUS  
CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 114 THERE ARE 114 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L8 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1972:473445 CAPLUS  
DOCUMENT NUMBER: 77:73445

TITLE: Plasma free fatty acids and obesity  
 AUTHOR(S): Badinand, A.; Losman, M.  
 CORPORATE SOURCE: Lab. Cent. Chim. Biol., Hop. E. Herriot, Lyons, Fr.  
 SOURCE: Bollettino Chimico Farmaceutico (1972), 111(3), 147-58  
 CODEN: BCFAAI; ISSN: 0006-6648  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Italian  
 AB Anal. of plasma free fatty acids and adipose tissue fatty acids of 8 human controls, 18 obese subjects, and 5 diabetics by thin-layer and gas chromatog. showed a higher concentration of stearic and palmitic acid in the plasma than in adipose tissue, particularly in obese subjects. In contrast, concentration of oleic acid is higher in adipose tissue. Its concentration is lowest in some obese subjects. The relatively high concentration of **phytanic acid** in plasma in comparison to adipose tissue indicate that its origin is not endogenous.  
 IT 14721-66-5  
 RL: BIOL (Biological study)  
     (of blood plasma, in obesity, **diabetes** in relation to)  
 RN 14721-66-5 CAPLUS  
 CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 15 OF 36 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN  
 ACCESSION NUMBER: 2003103483 EMBASE  
 TITLE: **Phytanic acid** alpha-oxidation, new insights into an old problem: A review.  
 AUTHOR: Wanders R.J.A.; Jansen G.A.; Lloyd M.D.  
 CORPORATE SOURCE: R.J.A. Wanders, Depts. Pediat./Emma Children's H., Academic Medical Centre, University Hospital Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, Netherlands.  
     r.j.wanders@amc.uva.nl  
 SOURCE: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, (17 Mar 2003) Vol. 1631, No. 2, pp. 119-135.  
     Refs: 91  
     ISSN: 1388-1981 CODEN: BBMLFG  
 COUNTRY: Netherlands  
 DOCUMENT TYPE: Journal; General Review  
 FILE SEGMENT: 030 Pharmacology  
               037 Drug Literature Index  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 ENTRY DATE: Entered STN: 25 Mar 2003  
               Last Updated on STN: 25 Mar 2003  
 AB **Phytanic acid** (3,7,10,14-tetramethylhexadecanoic acid) is a branched-chain fatty acid which is known to accumulate in a number of different genetic diseases including Refsum disease. Due to the presence of a methyl-group at the 3-position, **phytanic acid** and other 3-methyl fatty acids can not undergo  $\beta$ -oxidation but are first subjected to fatty acid  $\alpha$ -oxidation in which the terminal carboxyl-group is released as  $\text{CO}_2$ . The mechanism of  $\alpha$ -oxidation has long remained obscure but has been resolved in recent years. Furthermore, peroxisomes have been found to play an indispensable role in fatty acid  $\alpha$ -oxidation, and the complete  $\alpha$ -oxidation machinery is probably localized in peroxisomes. This Review describes the current state of knowledge about fatty acid  $\alpha$ -oxidation in mammals with


particular emphasis on the mechanism involved and the enzymology of the pathway. .COPYRGT. 2003 Elsevier Science B.V. All rights reserved.

L8 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:368900 CAPLUS  
 DOCUMENT NUMBER: 140:395235  
 TITLE: Nuclear hormone receptor compounds such as  
 β-ionol and fatty acid analogs for the treatment  
 of cancer and skin disorders.  
 INVENTOR(S): Delong, Mitchell Anthony; Biedermann, Kimberly Ann;  
 Bissett, Donald Lynn; Boyer, Angelique Sun; Cohen,  
 Scott Louis; Snider, Catherine Elizabeth  
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA  
 SOURCE: PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037213	A2	20040506	WO 2003-US34155	20031023
WO 2004037213	A3	20040729		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW,				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004131648	A1	20040708	US 2002-279397	20021024
CA 2500974	AA	20040506	CA 2003-2500974	20031023
AU 2003285042	A1	20040513.	AU 2003-285042	20031023
EP 1553916	A2	20050720	EP 2003-779359	20031023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1705468	A	20051207	CN 2003-80101584	20031023
JP 2006507287	T2	20060302	JP 2004-547235	20031023
PRIORITY APPLN. INFO.:			US 2002-279397	A 20021024
			WO 2003-US34155	W 20031023

OTHER SOURCE(S): MARPAT 140:395235


GI



AB Title compds. e.g. [I; X = single or double bonded moiety comprising 0-12 (substituted) C atoms, 0-2 heteroatoms; Z = single, double, or triple bonded moiety comprising 0-12 C atoms in a chain, optionally including (substituted) cycloalkyl, aryl rings; Y = (CH<sub>2</sub>)<sub>n</sub>; n = 0-3; R =

(substituted) alkyl, cycloalkyl, aryl], are claimed. (no synthetic data). Title compds. are believed to function as RXR, RAR and/or PPAR receptor ligands to encourage skin differentiation and discourage excess skin proliferation.

IT 14721-66-5, **Phytanic acid**  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
USES (Uses)  
(nuclear hormone receptor compds. such as  $\beta$ -ionol and fatty acid  
analogs for the treatment of cancer and skin disorders)  
RN 14721-66-5 CAPLUS  
CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1963:485146 CAPLUS  
DOCUMENT NUMBER: 59:85146  
ORIGINAL REFERENCE NO.: 59:15823e-g  
TITLE: The effect of N2-butylibiguanide (W 37) and  
N1-( $\beta$ -phenylethyl)biguanide (W 32) upon alioxan-  
and phlorizin-induced **diabetes** and the  
intestinal glucose absorption in rats  
AUTHOR(S): Creutzfeldt, W.; Soeling, H. D.; Moench, A.; Rauh, E.;  
Bol, M.  
CORPORATE SOURCE: Med. Univ.-Klin., Frieberg i. Br., Germany  
SOURCE: Archiv fuer Experimentelle Pathologie und  
Pharmakologie (1962), 244(1), 31-47  
CODEN: AEXPBL; ISSN: 0365-2041  
DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable  
AB Rats with alioxaninduced **diabetes** of over 4-months duration  
showed no noticeable blood sugar decrease for 4-8 hrs. after subcutaneous  
injection of either 80 mg. W-37/kg. or of 70 mg. W-32/kg. Three  
injections of 20-30 mg. W-37/kg. decreased glycosuria. This symptom is  
due not to an increase in glucose utilization, but to a change in kidney  
function. In rats, rendered diabetic by 3 daily doses of 250 mg.  
phlorizin/kg., W-37 caused no decrease in glycosuria. The effect of W-37  
on glucose absorption was tested by addition of 50-100 mg./kg. to  
glucose-filled small intestine, tied off *in situ*. No decrease in glucose  
absorption took place even after preliminary rinsing of the intestines  
with W-37. Administered subcutaneously, the same dose caused slight,  
temporary decrease in glucose absorption after 100-200 min. Stomach  
emptying time was prolonged by W-37. 26 references.

L8 ANSWER 18 OF 36 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
ACCESSION NUMBER: 2004:288048 BIOSIS  
DOCUMENT NUMBER: PREV200400286805  
TITLE: Induction of Inflammatory Markers in Epididymal Adipose  
Tissue of Diet-Induced Obese (DIO) C57BL/6J Mice: Impact of  
**Phytanic Acid** and BRL49653.  
AUTHOR(S): Teixeira, Sandra R [Reprint Author]; Preller, Mareike;  
Wang, Ying; Schwager, Joseph; Champy, Marie-France; Auwerx,  
Johan; Elste, Volker; Weber, Peter; Fluehmann, Beat  
CORPORATE SOURCE: R&AMPD Human Nutrition and Health, DSM Nutritional  
Products, P.O: Box 3255, Bldg 205/209B, Basel, 4002,  
Switzerland  
sandra-renata.teixeira@dsm.com

SOURCE: FASEB Journal, (2004) Vol. 18, No. 4-5, pp. Abst. 356.13.  
<http://www.fasebj.org/>. e-file.  
 Meeting Info.: FASEB Meeting on Experimental Biology:  
 Translating the Genome. Washington, District of Columbia,  
 USA. April 17-21, 2004. FASEB.  
 ISSN: 0892-6638 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)  
 Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 16 Jun 2004  
 Last Updated on STN: 16 Jun 2004

AB The innate immune system and the stimulation of acute-phase protein synthesis in liver have been postulated to contribute to insulin resistance and T2DM. In this study, we examined the effect of diet-induced obesity on gene expression of inflammatory markers in adipose tissue. 48 male C57BL/6J mice were assigned to 4 groups (n=12/group). One group received chow (lean control, LC), while 3 groups received a high-fat (HF) diet. One of the HF groups served as the fat control (FC), whereas the other 2 received additionally either **phytanic acid** at 150 mpk or BRL49653 at 10 mpk (TZD). Mice receiving HF became obese and diabetic during the study period. After 23wks, epididymal adipose tissue was collected from 6 mice/group and analyzed using Affymetrix Genechip. Genes known to be involved in inflammatory responses were selected and further filtered to include only those with change factors <-0.5 or >0.5 and p-value <0.05. HF diet resulted in upregulation of the acute-phase proteins haptoglobin, and orosomucoid 1 and 2, the lipopolysaccharide (LPS) binding protein, and heat-shock protein (HSP) 72. Treatment with either PPARgamma agonist resulted in a downregulation of the expression of most of these markers to levels close to LC. Other classical inflammatory markers were not regulated. Our results with selected inflammatory markers suggest that diet-induced obesity induces a persistent acute-phase reaction in adipose tissue, which may contribute to insulin-resistance. Moreover, the two investigated PPARgamma agonists can reduce the amount of inflammation, while improving metabolic status.

L8 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:412796 CAPLUS  
 DOCUMENT NUMBER: 140:395555  
 TITLE: Antidiabetic nutraceutical compositions comprising  
 epigallocatechin gallate  
 INVENTOR(S): Raederstorff, Daniel; Teixeira, Sandra Renata; Weber,  
 Peter  
 PATENT ASSIGNEE(S): DSM Ip Assets B.V., Neth.  
 SOURCE: PCT Int. Appl., 21 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041257	A2	20040521	WO 2003-EP10838	20030930
WO 2004041257	A3	20040805		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,			

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003293592	A1	20040607	AU 2003-293592	20030930
EP 1558244	A2	20050803	EP 2003-788928	20030930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1694695	A	20051109	CN 2003-824662	20030930
JP 2006508096	T2	20060309	JP 2004-548728	20030930
US 2006165671	A1	20060727	US 2005-533858	20051212

PRIORITY APPLN. INFO.: EP 2002-24804 A 20021107  
WO 2003-EP10838 W 20030930


AB The invention relates to nutraceutical compns. comprising at least two ingredients from the groups of epigallocatechin gallate, pantethine or a metabolite thereof, **phytanic acid**, lipoic acid, policosanol and coenzyme Q-10 and their use in the treatment or prevention of **diabetes** or obesity.

IT 14721-66-5, **Phytanic acid**

RL: FFD (Food or feed use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antidiabetic nutraceutical compns. comprising epigallocatechin gallate)

RN 14721-66-5 CAPLUS

CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 20 OF 36 MEDLINE on STN

ACCESSION NUMBER: 2004562288 MEDLINE

DOCUMENT NUMBER: PubMed ID: 15533633

TITLE: Nutraceutical resources for **diabetes** prevention--an update.

AUTHOR: McCarty Mark F

CORPORATE SOURCE: NutriGuard Research, 1051 Hermes Avenue, Encinitas, CA 92024, USA.. mccarty@pantox.com

SOURCE: Medical hypotheses, (2005) Vol. 64, No. 1, pp. 151-8.  
Journal code: 7505668. ISSN: 0306-9877.

PUB. COUNTRY: Scotland: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200504

ENTRY DATE: Entered STN: 10 Nov 2004

Last Updated on STN: 22 Apr 2005

Entered Medline: 21 Apr 2005

AB There is considerable need for safe agents that can reduce risk for **diabetes** in at-risk subjects. Although certain drugs--including metformin, acarbose, and orlistat--have shown **diabetes** -preventive activity in large randomized studies, nutraceuticals have potential in this regard as well. Natural agents which slow carbohydrate absorption may mimic the protective effect of acarbose; these include: soluble fiber--most notably glucomannan; chlorogenic acid--likely responsible for reduction in **diabetes** risk associated with heavy coffee intake; and legume-derived alpha-amylase inhibitors. There does not appear to be a natural lipase inhibitor functionally equivalent to orlistat, although there are poorly documented claims for Cassia nomame extracts. Metformin's efficacy reflects activation of AMP-activated kinase; there is preliminary evidence that certain compounds in barley malt have similar activity, without the side effects associated with metformin. In supraphysiological concentrations, biotin directly


activates soluble guanylate cyclase; this implies that, at some sufficient intake, biotin should exert effects on beta cells, the liver, and skeletal muscle that favor good glucose tolerance and maintenance of effective beta cell function. Good magnesium status is associated with reduced **diabetes** risk and superior insulin sensitivity in recent epidemiology; ample intakes of chromium picolinate appear to promote insulin sensitivity in many individuals and improve glycemic control in some diabetics; calcium/vitamin D may help preserve insulin sensitivity by preventing secondary hyperparathyroidism. Although conjugated linoleic acid-like thiazolidinediones, a PPAR-gamma agonist--has not aided insulin sensitivity in clinical trials, the natural rexinoid **phytanic acid** exerts thiazolidinedione-like effect in animals and cell cultures, and merits clinical examination. Other natural agents with the potential to treat and possibly prevent **diabetes** include extracts of bitter melon and of cinnamon. Nutraceuticals featuring meaningful doses of combinations of these agents would likely have substantial **diabetes**-preventive efficacy, and presumably could be marketed legally as aids to good glucose tolerance and insulin sensitivity.

L8 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:849656 CAPLUS  
 DOCUMENT NUMBER: 137:338098  
 TITLE: Preparation of pharmaceutically active uridine ester nucleosides against a variety of diseases  
 INVENTOR(S): Susilo, Rudy  
 PATENT ASSIGNEE(S): Germany  
 SOURCE: PCT Int. Appl., 73 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088159	A1	20021107	WO 2002-EP4725	20020429
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2445861	AA	20021107	CA 2002-2445861	20020429
EE 200300536	A	20040216	EE 2003-536	20020429
EP 1390378	A1	20040225	EP 2002-766645	20020429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1505636	A	20040616	CN 2002-809160	20020429
BR 2002009320	A	20040720	BR 2002-9320	20020429
JP 2004531543	T2	20041014	JP 2002-585457	20020429
NZ 528634	A	20050429	NZ 2002-528634	20020429
EP 1666092	A2	20060607	EP 2005-17150	20020429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, MK, CY, AL, TR				
NO 2003004782	A	20031212	NO 2003-4782	20031024
US 2004121979	A1	20040624	US 2003-476287	20031029
BG 108299	A	20040930	BG 2003-108299	20031029
ZA 2003008420	A	20041029	ZA 2003-8420	20031029
US 2005043269	A1	20050224	US 2004-951764	20040929

US 2005043394	A1	20050224	US 2004-951776	20040929
US 2005065110	A1	20050324	US 2004-951724	20040929
AU 2006200874	A1	20060323	AU 2006-200874	20060301
PRIORITY APPLN. INFO.:				
			EP 2001-110608	A 20010430
			US 2001-288090P	P 20010503
			EP 2001-124879	A 20011018
			US 2001-330429P	P 20011022
			EP 2002-766645	A3 20020429
			WO 2002-EP4725	W 20020429
			US 2003-476287	A3 20031029

OTHER SOURCE(S): MARPAT 137:338098  
GI




AB The present invention relates to novel uridine esters I, wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R<sup>1</sup> represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a variety of diseases, methods for the preparation of said uridine esters and pharmaceutical compns. containing at least one uridine ester as active ingredient. The present invention relates also to a drug combination comprising free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate and/or deoxyuridine monophosphate, and to the use of such a drug combination. Thus, I [R = OCO(CH<sub>2</sub>CH<sub>2</sub>)<sub>6</sub>Et, R<sup>1</sup> = OH] was prepared and tested in NMRI mice against a variety of diseases such as **diabetes**, polyneuropathy, and neuroprotective effects. Title compds were prepared as stimulant drug and/or for prophylaxis and/or treatment of **diabetes mellitus** Type I and Type II, inflammation, cancer, necrosis, gastric ulcers, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease), neuropathic diseases, neuropathic pain and polyneuropathy, peripheral and/or central nerve diseases, degradation of the peripheral and/or central nerve system, heavy metal poisoning, ischemic diseases and ischemic heart disease, liver diseases and dysfunction of liver, allergies, cardiovascular diseases, Chlamydia pneumoniae, depression, obesity, stroke, pain, and/or retroviral infections (HIV, AIDS), including opportunistic infections. Dihomo- $\gamma$ -linolenic acid Arachidonic acid 7,10,13,16-Docosatetraenoic acid  $\alpha$ -Linolenic acid Stearidonic acid 8,11,14,17-Eicosatetraenoic acid  $\gamma$ -Linolenic acid.

IT 14721-66-5, **Phytanic acid**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of)

RN 14721-66-5 CAPLUS

CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2006:795639 CAPLUS  
 DOCUMENT NUMBER: 145:195780  
 TITLE: Compositions comprising epigallocatechin gallate and protein hydrolysate  
 INVENTOR(S): Wolfram, Swen  
 PATENT ASSIGNEE(S): DSM IP Assets B.V., Neth.  
 SOURCE: PCT Int. Appl., 38pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082222	A1	20060810	WO 2006-EP50623	20060202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2005-100755 A 20050203  
 AB The present invention describes a composition comprising EGCG and a protein hydrolysate.  
 IT 14721-66-5, Phytanic acid  
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);  
 USES (Uses)  
 (comprns. comprising epigallocatechin gallate and protein hydrolysate)  
 RN 14721-66-5 CAPLUS  
 CN Hexadecanoic acid, 3,7,11,15-tetramethyl- (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:737602 CAPLUS  
 DOCUMENT NUMBER: 139:244708  
 TITLE: Immunomodulatory polymeric antigens for treating inflammatory diseases  
 INVENTOR(S): Taylor, Kathleen Ann; Blaszczak, Larry Chris;

PATENT ASSIGNEE(S): Blackburn, Neil Thomas  
SOURCE: Eli Lilly and Company, USA  
DOCUMENT TYPE: PCT Int. Appl., 96 pp.  
LANGUAGE: CODEN: PIXXD2  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION: Patent  
English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003075953	A2	20030918	WO 2003-US5575	20030307
WO 2003075953	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003217685	A1	20030922	AU 2003-217685	20030307
EP 1494687	A2	20050112	EP 2003-713643	20030307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005119164	A1	20050602	US 2003-506312	20030307
PRIORITY APPLN. INFO.:				
			US 2002-363065P	P 20020308
			US 2002-365211P	P 20020315
			WO 2003-US5575	W 20030307

AB Provided are natural and synthetic immunomodulatory polymeric antigens (SPAs); compns. containing SPAs, *Streptococcus pneumoniae* capsule-derived CP1 and mixts.; as well as methods of using these natural and synthetic SPAs and compns. to prevent or treat inflammatory pathologies. A novel synthetic peptidoglycan was prepared for the purpose of the invention.

IT 150-86-7, Phytol


RL: RCT (Reactant); RACT (Reactant or reagent)  
(immunomodulatory polymeric antigens for treating inflammatory diseases)

RN 150-86-7 CAPLUS

CN 2-Hexadecen-1-ol, 3,7,11,15-tetramethyl-, (2E,7R,11R)- (9CI) (CA INDEX NAME)

### Absolute stereochemistry.

Double bond geometry as shown.



L8 ANSWER 24 OF 36 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001263903 EMBASE

## **TITLE: PPAR $\gamma$ /RXR as a molecular target for diabetes**

AUTHOR: Lenhard J.M.

CORPORATE SOURCE: J.M. Lenhard, Department of Metabolic Diseases,  
GlaxoSmithKline Inc., 5 Moore Drive, Research Triangle  
Park, NC 27709. United States

SOURCE: Receptors and Channels, (2001) Vol. 7, No. 4, pp. 249-258.

Refs: 141

ISSN: 1060-6823 CODEN: RCHAE4

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 003 Endocrinology

006 Internal Medicine

030 Pharmacology

037 Drug Literature Index

038 Adverse Reactions Titles

052 Toxicology

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 16 Aug 2001

Last Updated on STN: 16 Aug 2001

AB Type 2 **diabetes** is associated with insulin resistance in peripheral tissues, such as muscle and fat. Novel therapies that improve insulin action include ligands that bind and activate the nuclear receptors peroxisome proliferator activating receptor  $\gamma$  (PPAR $\gamma$ ) and retinoid X receptor (RXR). PPAR $\gamma$ /RXR form heterodimers that regulate transcription of genes involved in insulin action, adipocyte differentiation, lipid metabolism and inflammation. PPAR $\gamma$  activators include prostanoids, fatty acids, thiazolidinediones and N-(2-benzoylphenyl)tyrosine analogues. RXR ligands include naturally occurring retinoic acid and synthetic rexinoids. Selective ligands for these receptors improve metabolic abnormalities associated with type 2 **diabetes**, such as hyperglycemia, hyperlipidemia, insulin resistance and other cardiovascular risk factors. Although adipose tissue mediates some of the effects of PPAR $\gamma$ /RXR ligands, other tissues also regulate the effects of these receptors. The activity of the PPAR $\gamma$ /RXR heterodimer is influenced by posttranslational modifications, receptor turnover, polymorphisms, splice variants, coactivators and corepressors. This article reviews recent developments in research on these receptors, with particular emphasis on metabolic effects, ligand selectivity, structure and regulation of the PPAR $\gamma$ /RXR heterodimer.

L8 ANSWER 25 OF 36 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2006:154697 BIOSIS

DOCUMENT NUMBER: PREV200600162521

TITLE: **Phytanic acid** improves metabolic parameters and modulates hepatic gene expression in vivo (DIO C57BL/6J mice).

AUTHOR(S): Preller, Mareike [Reprint Author]; Wang, Ying; Champy, Marie-France; Auwerx, Johan; Elste, Volker; Fluehmann, Beat; Weber, Peter; Teixeira, Sandra

SOURCE: Diabetes, (JUN 2004) Vol. 53, No. Suppl. 2, pp. A266. Meeting Info.: 64th Annual Meeting of the American-Diabetes-Association. Orlando, FL, USA. June 04-08, 2004. Amer Diabet Assoc.

CODEN: DIAEAZ. ISSN: 0012-1797.

DOCUMENT TYPE: Conference; (Meeting)

Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 9 Mar 2006

Last Updated on STN: 9 Mar 2006

L8 ANSWER 26 OF 36 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002164911 EMBASE

TITLE: The mode of action of thiazolidinediones.

AUTHOR: Hauner H.  
CORPORATE SOURCE: H. Hauner, German Diabetes Research Institute,  
Heinrich-Heine University, Auf'm Hennekamp 65, D-40225  
Dusseldorf, Germany. hauner@dfi.uni-duesseldorf.de  
SOURCE: Diabetes/Metabolism Research and Reviews, (2002) Vol. 18,  
No. SUPPL. 2, pp. S10-S15. .  
Refs: 59  
ISSN: 1520-7552 CODEN: DMRRFM  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 003 Endocrinology  
022 Human Genetics  
030 Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 23 May 2002  
Last Updated on STN: 23 May 2002

AB The thiazolidinediones (TZDs) or 'glitazones' are a new class of oral antidiabetic drugs that improve metabolic control in patients with type 2 diabetes through the improvement of insulin sensitivity. TZDs exert their antidiabetic effects through a mechanism that involves activation of the gamma isoform of the peroxisome proliferator-activated receptor (PPAR $\gamma$ ), a nuclear receptor. TZD-induced activation of PPAR $\gamma$  alters the transcription of several genes involved in glucose and lipid metabolism and energy balance, including those that code for lipoprotein lipase, fatty acid transporter protein, adipocyte fatty acid binding protein, fatty acyl-CoA synthase, malic enzyme, glucokinase and the GLUT4 glucose transporter. TZDs reduce insulin resistance in adipose tissue, muscle and the liver. However, PPAR $\gamma$  is predominantly expressed in adipose tissue. It is possible that the effect of TZDs on insulin resistance in muscle and liver is promoted via endocrine signalling from adipocytes. Potential signalling factors include free fatty acids (FFA) (well-known mediators of insulin resistance linked to obesity) or adipocyte-derived tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ), which is overexpressed in obesity and insulin resistance. Although there are still many unknowns about the mechanism of action of TZDs in type 2 diabetes, it is clear that these agents have the potential to benefit the full 'insulin resistance syndrome' associated with the disease. Therefore, TZDs may also have potential benefits on the secondary complications of type 2 diabetes, such as cardiovascular disease. Copyright .COPYRGT. 2002 John Wiley & Sons, Ltd.

L8 ANSWER 27 OF 36 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on  
STN  
ACCESSION NUMBER: 1993:321644 BIOSIS  
DOCUMENT NUMBER: PREV199396029994  
TITLE: Complementation analysis of patients with intact peroxisomes and impaired peroxisomal beta-oxidation.  
AUTHOR(S): McGuinness, M. C. [Reprint author]; Moser, A. B. [Reprint author]; Poll-The, B. T.; Watkins, P. A. [Reprint author]  
CORPORATE SOURCE: Kennedy Krieger Inst., Johns Hopkins Univ. Sch. Med.,  
Baltimore, MD 21205, USA  
SOURCE: Biochemical Medicine and Metabolic Biology, (1993) Vol. 49,  
No. 2, pp. 228-242.  
CODEN: BMMBES. ISSN: 0885-4505.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 12 Jul 1993

Last Updated on STN: 31 Aug 1993

AB Complementation analysis, using peroxisomal beta-oxidation of very long chain fatty acids (VLCFA) as the criterion for complementation, is useful

in the study of patients who are suspected of having a single enzyme defect in the peroxisomal beta-oxidation pathway. Laboratory findings for these patients include elevated plasma VLCFA and impaired VLCFA oxidation in fibroblasts. Some of these patients have slightly abnormal phytanic acid oxidation in fibroblasts. In addition, elevated levels of bile acid intermediates have been reported in some cases. Plasmalogen synthesis, pipecolic acid levels, and subcellular distribution of catalase are normal. Using complementation analysis, we show that six patients, who were suspected of having a single enzyme defect in the peroxisomal beta-oxidation pathway, are deficient in peroxisomal bifunctional enzyme (enoyl-CoA hydratase (EC 4.2.1.17)/3-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.35)) activity. This group of six patients, deficient in bifunctional enzyme activity, may be subdivided into two complementation groups. It would appear that patients in each of these two groups are deficient in only one of the bifunctional enzyme activities.

L8 ANSWER 28 OF 36 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005055864 EMBASE  
TITLE: Thiazolidinediones.  
AUTHOR: Bloomgarden Z.T.  
CORPORATE SOURCE: Dr. Z.T. Bloomgarden, Diabetes Center, Mount Sinai School of Medicine, New York, NY, United States  
SOURCE: Diabetes Care, (2005) Vol. 28, No. 2, pp. 488-493. .  
Refs: 11  
ISSN: 0149-5992 CODEN: DICAD2  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Conference Article  
FILE SEGMENT: 003 Endocrinology  
006 Internal Medicine  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: English  
ENTRY DATE: Entered STN: 18 Feb 2005  
Last Updated on STN: 18 Feb 2005  
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L8 ANSWER 29 OF 36 MEDLINE on STN

ACCESSION NUMBER: 1999352945 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 10424146  
TITLE: A case of motor and sensory polyneuropathy with retinitis pigmentosa and diffuse idiopathic skeletal hyperostosis.  
AUTHOR: Osoegawa M; Araki E; Arakawa K; Okayama A; Yamada T; Ohnishi A; Kira J  
CORPORATE SOURCE: Department of Neurology, Faculty of Medicine, Kyushu University.  
SOURCE: Rinsho shinkeigaku = Clinical neurology, (1999 May) Vol. 39, No. 5, pp. 542-5.  
Journal code: 0417466. ISSN: 0009-918X.  
PUB. COUNTRY: Japan  
DOCUMENT TYPE: (CASE REPORTS)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: Japanese  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199909  
ENTRY DATE: Entered STN: 12 Oct 1999  
Last Updated on STN: 3 Mar 2000  
Entered Medline: 24 Sep 1999

AB We here report a 53-year-old man who presented with motor and sensory polyneuropathy, retinitis pigmentosa and diffuse idiopathic skeletal hyperostosis (DISH). He had a 15-year history of diabetes mellitus (DM). Visual impairment appeared at 17 years of age. Since age

47, he showed a slowly progressive sensory impairment and muscle weakness of the extremities. On neurological examination, retinitis pigmentosa and severe muscle atrophy, muscle weakness and sensory disturbance of all modalities in the distal portions of all four extremities were observed. Deep tendon reflexes were absent. A plain X-P showed diffuse ossification of the spinal and extraspinal ligaments. The motor nerve conduction velocities were severely reduced and no sensory nerve action potentials were evoked. The CSF examination revealed an increased protein level without pleocytosis. The sural nerve biopsy showed a marked onion bulb formation and a loss of the myelinated nerve fibers, which could not be solely explained by DM. As the **phytanic acids** levels, beta-lipoprotein, lactate and pyruvate in the sera were within the normal ranges, Refsum disease, Bassen-Kornzweig syndrome and mitochondrial diseases were unlikely in this patient. The presence of demyelinating and axonal polyneuropathy in this patient may have been caused by a common metabolic disturbance which produced both retinitis pigmentosa and DISH.

L8 ANSWER 30 OF 36 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004518203 EMBASE

TITLE: Diet, fatty acids, and regulation of genes important for heart disease.

AUTHOR: Vanden Heuvel J.P.

CORPORATE SOURCE: Dr. J.P. Vanden Heuvel, Department of Veterinary Sciences, Ctr. Molec. Toxicol./Carcinogenesis, Pennsylvania State University, 226 Fenske Laboratory, University Park, PA 16802, United States. [jpv2@psu.edu](mailto:jpv2@psu.edu)

SOURCE: Current Atherosclerosis Reports, (2004) Vol. 6, No. 6, pp. 432-440. .

Refs: 85

ISSN: 1523-3804 CODEN: CARUCZ

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery  
030 Pharmacology  
037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 28 Dec 2004  
Last Updated on STN: 28 Dec 2004

AB Diets rich in omega-3 polyunsaturated fatty acids (n-3 PUFAs), such as alpha-linoleic acid, eicosapentaenoic acid, and docosahexaenoic acid, are associated with decreased incidence and severity of coronary heart disease. Similarly, conjugated linoleic acids (CLAs), which are found in meat and dairy products, have beneficial effects against atherosclerosis, **diabetes**, and obesity. The effects of n3-PUFAs and CLAs are in contrast to fatty acids with virtually identical structures, such as linoleic acid and arachidonic acid (ie, n-6 PUFAs). This article discusses the possibility that cognate receptors exist for fatty acids or their metabolites that are able to regulate gene expression and coordinately affect metabolic or signaling pathways associated with coronary heart disease. Three nuclear receptors are emphasized as fatty acid receptors that respond to dietary and endogenous ligands: peroxisome proliferator activated receptors, retinoid X receptors, and liver X receptors. Copyright .COPYRGT. 2004 by Current Science Inc.

L8 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:319452 CAPLUS

DOCUMENT NUMBER: 138:314630

TITLE: Orthomolecular sulfo-adenosylmethionine derivatives with antioxidant properties

INVENTOR(S): Wilburn, Michael D.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 17 pp.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003078231	A1	20030424	US 2001-886612	20010622
PRIORITY APPLN. INFO.:			US 2001-886612	20010622
OTHER SOURCE(S):	MARPAT 138:314630			
GI				



AB Disclosed are orthomol. sulfo-adenosylmethionine derivative compds., compns., and their uses for effecting a biol. activity in an animal, such as neurochem. activity; liver biol. activity; heart and artery function; cartilage, bone and joint health; stomach and/or intestinal lining resistance to ulceration; immune function; cell membrane integrity; and pain and inflammation. The compds. of the present invention are further useful for preventing or treating diseases or conditions; treating viral infections, infectious diseases, leukemia, and obesity; and reducing the risk of Sudden Infant Death Syndrome in an animal. The compds. of the present invention are I (R<sub>1</sub> = H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl or alkynyl, -C(O)R<sub>2</sub>; R<sub>2</sub> = C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl or alkynyl; Q = -C(NH<sub>3</sub>)C(O)AX, -C(COOH)NHX; A = O, N; X = a defined reaction product) or pharmaceutically acceptable salt, ester or solvate thereof.  $\alpha$ -(S-adenosylmethionine)-O-tocopherol was prepared from N-Acetyl-S-benzyl-L-homocysteine,  $\alpha$ -tocopherol, and 5'-O-p-Tolylsulfonyladenosine.

L8 ANSWER 32 OF 36 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003409284 EMBASE

TITLE: Reviews: Current topics role of nuclear receptors in the regulation of gene expression by dietary fatty acids (review).

AUTHOR: Khan S.A.; Vanden Heuvel J.P.

CORPORATE SOURCE: J.P. Vanden Heuvel, Department of Veterinary Science, Ctr. Molec. Toxicol./Carcinogenesis, Penn State University, University Park, PA 16802, United States. jpv2@psu.edu

SOURCE: Journal of Nutritional Biochemistry, (1 Oct 2003) Vol. 14, No. 10, pp. 554-567. .

Refs: 142

ISSN: 0955-2863 CODEN: JNBIEL

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 030 Pharmacology

037 Drug Literature Index

LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 23 Oct 2003  
Last Updated on STN: 23 Oct 2003

AB Long chain fatty acids, derived either from endogenous metabolism or by nutritional sources play significant roles in important biological processes of membrane structure, production of biologically active compounds, and participation in cellular signaling processes. Recently, the structure of dietary fatty acids has become an important issue in human health because ingestion of saturated fats (containing triglycerides composed of saturated fatty acids) is considered harmful, while unsaturated fats are viewed as beneficial. It is important to note that the molecular reason for this dichotomy still remains elusive. Since fatty acids are important players in development of pathology of cardiovascular and endocrine system, understanding the key molecular targets of fatty acids, in particular those that discriminate between saturated and unsaturated fats, is much needed. Recently, insights have been gained on several fatty acid-activated nuclear receptors involved in gene expression. In other words, we can now envision long chain fatty acids as regulators of signal transduction processes and gene regulation, which in turn will dictate their roles in health and disease. In this review, we will discuss fatty acid-mediated regulation of nuclear receptors. We will focus on peroxisome proliferators-activated receptors (PPARs), liver X receptors (LXR), retinoid X receptors (RXRs), and Hepatocyte Nuclear Factor alpha (HNF-4 $\alpha$ ), all of which play pivotal roles in dietary fatty acid-mediated effects. Also, the regulation of gene expression by Conjugated Linoleic Acids (CLA), a family of dienoic fatty acids with a variety of beneficial effects, will be discussed.

.COPYRGT. 2003 Elsevier Inc. All rights reserved.

L8 ANSWER 33 OF 36 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 80174252 EMBASE  
DOCUMENT NUMBER: 1980174252  
TITLE: [Vegetable oils - analysis and dietary application].  
PFLANZLICHE OLE - IHRE ANALYTIK UND DIATETISCHE VERWENDUNG.  
AUTHOR: Schilcher H.; Nissler A.  
CORPORATE SOURCE: Wissenschaftl. Abt., Johann Georg Fink GmbH & Co., D-7033  
Heilbronn, Germany  
SOURCE: Physikalische Medizin und Rehabilitation, (1980) Vol. 21,  
No. 3, pp. 141-156.  
CODEN: PMDRBC  
COUNTRY: Germany  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
019 Rehabilitation and Physical Medicine  
LANGUAGE: German  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 9 Dec 1991  
Last Updated on STN: 9 Dec 1991

AB Not only former epidemiological investigations but also some new studies have shown how important vegetable oils with a high content of polyunsaturated fatty acids can be in the medical practice. In the following fields of application, suitable vegetable oils are indicated. In case of existing hyperlipidemia (particularly types II and IV depending on nutrition), i.e., if, apart from therapeutic treatment, it is absolutely necessary to influence the serum cholesterol level in a dietary manner. As additional dietary treatment of an existing arteriosclerosis and as preventive modulation of arteriosclerotic risk factors. As additional dietary treatment in case of hypertension and age-induced diabetes mellitus. For the replacement of animal fats which, in contrast to vegetable oils, are rich in saturated fatty acids, in case of adiposis (during a reduction diet one has to renounce saturated fatty

acids) and in case of bile and liver diseases as vegetable oils are more easily compatible. Generally, as part of a healthy nutrition because such a diet must contain all the essential nutrients and therefore also polyunsaturated fatty acids sufficiently. Based on several analytic data, one cannot only establish the physiological value of vegetable oils but can also draw conclusions on the manufacturing method and the refining process.

L8 ANSWER 34 OF 36 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2006073515 EMBASE

TITLE: Decoding the pyramid: A systems-biological approach to nutrigenomics.

AUTHOR: Kaput J.

CORPORATE SOURCE: Dr. J. Kaput, Laboratory of High Speed Computing and Informatics, NCMHD Center of Excellence in Nutritional Genomics, University of California, Davis, One Shields Avenue, Davis, CA 95616, United States. jkaput@ucdavis.edu

SOURCE: Annals of the New York Academy of Sciences, (2005) Vol. 1055, pp. 64-79. .

Refs: 44

ISSN: 0077-8923 CODEN: ANYAA

COUNTRY: United States

DOCUMENT TYPE: Journal; Conference Article

FILE SEGMENT: 003 Endocrinology  
017 Public Health, Social Medicine and Epidemiology  
020 Gerontology and Geriatrics  
021 Developmental Biology and Teratology  
022 Human Genetics

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 10 Mar 2006  
Last Updated on STN: 10 Mar 2006

AB Nutritional genomics, or nutrigenomics, seeks to understand the effects of diet on an individual's genes and health. Nutrigenomics is a systems-biological science that can be explained by five principal tenets: (1) improper diets in some individuals and under some conditions are risk factors for chronic diseases; (2) common dietary chemicals alter gene expression and/or genome structure; (3) the influence of diet on health depends upon an individual's genetic makeup; (4) some genes or their normal common variants are regulated by diet, which may play a role in chronic diseases; and (5) dietary interventions based upon knowledge of nutritional requirements, nutritional status, and genotype can be used to develop individualized nutrition plans that optimize health and prevent or mitigate chronic diseases. Optimal nutrition may also influence the aging process. .COPYRGT. 2005 New York Academy of Sciences.

L8 ANSWER 35 OF 36 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005491091 EMBASE

TITLE: Urological oncology: Prostate cancer.

AUTHOR: Walsh P.C.

SOURCE: Journal of Urology, (2005) Vol. 174, No. 5, pp. 1823-1826.

ISSN: 0022-5347 CODEN: JOURAA

COUNTRY: United States

DOCUMENT TYPE: Journal; Note

FILE SEGMENT: 016 Cancer  
017 Public Health, Social Medicine and Epidemiology  
028 Urology and Nephrology  
029 Clinical Biochemistry

LANGUAGE: English

ENTRY DATE: Entered STN: 1 Dec 2005

Last Updated on STN: 1 Dec 2005  
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L8 ANSWER 36 OF 36 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 79210583 EMBASE

DOCUMENT NUMBER: 1979210583

TITLE: [Course of Refsum's disease treated by diet].  
REFSUM KRANKHEIT UND IHR VERLAUF BEI DIATETISCHER  
BEHANDLUNG DURCH 2.5 JAHRE. KLINIK, BIOCHEMISCHE UND  
NEUROPATHOLOGISCHE DATEN.

AUTHOR: Lenz H.; Sluga E.; Bernheimer H.; et al.

CORPORATE SOURCE: Neurol. Inst., Univ. Wien, Austria

SOURCE: Nervenarzt, (1979) Vol. 50, No. 1, pp. 52-60. .

CODEN: NERVAF

COUNTRY: Germany

DOCUMENT TYPE: Journal

FILE SEGMENT: 037 Drug Literature Index  
008 Neurology and Neurosurgery  
029 Clinical Biochemistry  
022 Human Genetics

LANGUAGE: German

SUMMARY LANGUAGE: English

AB A report is given on the first case of Refsum disease observed in Austria. Treatment for it lasted 2 1/2 years. This was dietetic (Steinberg-/Stokke diet, plasmapheresis), which brought improvement of the clinical, biochemical and electrophysiological changes. Comparative bioptic examinations on the sural nerve made it possible to recognize and analyze widespread demyelinations and showed a regression of these and also considerable remyelinations and regenerations after almost 2 years' diet. The difficulties of dietetic therapy are examined in detail, and also its restorative effects on peripheral nerve tissue. There is a discussion on the relationship between the quantity of the biochemical changes and the manifestation of symptom-provoking changes with regard to the myelin.

=>